Decentralized Clinical Trials: Implications for Biotech

Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits—and this is especially true for small or emerging biotechs with limited shots on goal. But by separating fact from fiction and understanding how to identify fit for purpose solutions, these companies can lay the roadmap for successful implementation of a decentralized clinical trial (DCT) strategy. Stephanie Gonzalez, Senior Vice President and Head of Global Biotech Solutio...